A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck - MacDonald, G C; Rasamoelisolo, M; Entwistle, J (Drug Des Devel Ther, 2009)
, et al.